Sierra Oncology's book value per share for the quarter that ended in Mar. 2022 was $10.99.
During the past 12 months, Sierra Oncology's average Book Value Per Share Growth Rate was 33.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -50.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -46.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Sierra Oncology was -30.20% per year. The lowest was -50.50% per year. And the median was -43.20% per year.
Sierra Oncology's current price is $54.99. Its book value per share for the quarter that ended in Mar. 2022 was $10.99. Hence, today's PB Ratio of Sierra Oncology is 5.00.
During the past 9 years, the highest P/B Ratio of Sierra Oncology was 8.39. The lowest was 1.05. And the median was 2.91.
Sierra Oncology Book Value per Share Historical Data
The historical data trend for Sierra Oncology's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sierra Oncology's Book Value per Share
For the Biotechnology subindustry, Sierra Oncology's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sierra Oncology's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sierra Oncology's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sierra Oncology's PB Ratio falls into.
Sierra Oncology Book Value per Share Calculation
Sierra Oncology's Book Value Per Share for the fiscal year that ended in Dec. 2021 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Sierra Oncology (NAS:SRRA) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Sierra Oncology Book Value per Share Related Terms
Thank you for viewing the detailed overview of Sierra Oncology's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Sierra Oncology (Sierra Oncology) Business Description
Sierra Oncology Inc is a clinical-stage drug development company. It focuses on the research, development, and commercialization of DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. In addition, it also engaged in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in the preclinical development stage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SRRA has been successfully added to your 